FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo
January 26, 2022
(Reuters) -Abbott Laboratories on Wednesday reported a 7.2% rise in quarterly sales on strong demand for diagnostics products, including its COVID-19 tests, led by a sharp surge in cases due to the Omicron variant.
The company’s net earnings fell to $1.99 billion, or $1.11 per share, in the fourth quarter ended Dec. 31 from $2.16 billion, $1.20 per share, a year earlier.
Sales of the company were $11.5 billion, higher than the $10.7 billion reported in the year-ago period.
(Reporting by Leroy Leo; Editing by Maju Samuel)
Source: One America News Network
